耐甲氧西林金黄色葡萄球菌致骨髓炎患者抗感染治疗的药学监护及其体会

Pharmaceutical Care of Anti-infection Treatment for Patients with Osteomyelitis Caused by Methicillin-resistant Staphylococcus Aureus and Its Experience

目的:分析耐甲氧西林金黄色葡萄球菌(methicillin-resistant Staphylococcus aureus,MRSA)致骨髓炎患者药物治疗的药学监护过程,以期为临床合理用药提供参考。方法:临床药师参与临床MRSA致骨髓炎患者的临床会诊与治疗,阐述药师参与治疗的临床思维,分析药学服务的切入点。结果:药师发挥药学专业特长,提出优化给药方案并参与药物不良反应的监测,患者血流感染到控制,血菌培养呈阴性,病情稳定出院。结论:临床药师参与治疗方案的优化,提高了社区获得性MRSA治疗效果,避免相关药品不良反应的发生。

Objective: To analyze the pharmaceutical care process of medications in patients osteomyelitis caused by methicillin-resistant Staphylococcus aureus(MRSA) so as to provide reference for clinical rational drug of usage.Methods: Clinical pharmacists participated in the clinical consultation and treatment of patients with clinical MRSA osteomyelitis, elaborated the clinical thinking of pharmacists participating in treatment, and analyzed the pharmaceutical care entry point. Results: Pharmacists gave full play to their specialty in pharmacy, put forward optimized drug administration plan and participated in the monitoring of adverse drug reactions. Patients’ bloodstream infection was controlled, blood bacteria culture was negative, and their condition was stable and discharged. Conclusion: The therapeutic schedules optimized by clinical pharmacists could improve the efficacy of patients with MRSA osteomyelitis and avoid the occurrence of the related adverse reactions.